

**AMENDMENTS TO THE CLAIMS:**

Without prejudice or disclaimer, the following listing of claims will replace all prior versions, and listing, of claims in this application:


**Listing of claims:**

**Claims 1-55 Cancelled.**

56. (Currently Amended) A compound represented by the formula (II):




or its prodrug; or a pharmaceutically acceptable salt or solvate thereof, wherein  $X^2$  is an optionally substituted 5-member thiazole ring heteroaryl or a thiazole group represented by the formula:



wherein E is  $-(\text{CH}_2)_{1-3}-$ ,  $-\text{O}-\text{CH}_2-$ , or  $-\text{S}-\text{CH}_2-$ ;

R<sup>6</sup> and R<sup>7</sup> are each independently a hydrogen atom, an optionally substituted lower alkyl, a carboxy, a lower alkyloxycarbonyl, an optionally substituted aminocarbonyl, an optionally substituted thienyl, or an optionally substituted phenyl;

$$Y^2 \text{ is } -NR^GCO-(CH_2)_{0-2}-, \text{ } \cancel{NR^GCO-(CH_2)_{0-2}-W}, \text{ } \cancel{NR^GCO-CH=CH-},$$
~~$$W(CH_2)_{4-5}NR^GCO(CH_2)_{0-2}, W(CH_2)_{4-5}CONR^G(CH_2)_{0-2}, CONR^G(CH_2)_{0-2},$$~~
$$-(\text{CH}_2)_{0-5}-\text{NR}^G-\text{SO}_2-(\text{CH}_2)_{0-5}-, (\text{CH}_2)_{0-5}-\text{SO}_2-\text{NR}^G-(\text{CH}_2)_{0-5}-, \text{NR}^G-(\text{CH}_2)_{0-2}-,$$
~~NR<sup>G</sup>CO-NR<sup>G</sup>, NR<sup>G</sup>CS-NR<sup>G</sup>, N=C(SR<sup>G</sup>)-NR<sup>G</sup>, NR<sup>G</sup>CSNR<sup>G</sup>CO,~~




wherein  $\text{R}^{\text{G}}$  is each independently a hydrogen atom or an optionally substituted lower alkyl,

~~$\text{R}^{\text{F}}$  is a hydrogen atom or an optionally substituted aryl, and~~

~~$\text{W}$  is an oxygen atom or a sulfur atom;~~

~~$\text{Z}^2$  is an optionally substituted phenylene, an optionally substituted 2,5-pyridine-diyl, an optionally substituted 2,5-thiophene-diyl, or an optionally substituted 2,5-furan-diyl;~~

$\text{A}^2$  is a thiazolidine ring represented by the formula:




wherein  $\text{R}^1$  and  $\text{R}^2$  are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom,  $\text{R}^3$  and  $\text{R}^4$  are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom, and  $\text{R}^5$  is a hydrogen atom or lower alkyl;

~~$\text{Q}$  and  $\text{V}$  are each independently chosen from  $\text{O}$ ,  $\text{S}$ ,  $\text{CH}_2$ , or  $\text{NR}^{\text{B}}$ , wherein  $\text{R}^{\text{B}}$  is a hydrogen atom or lower alkyl;~~


$m$  is 1, 2, or 3; and

a broken line ( --- ) represents the presence or absence of a bond;

~~with the provisos that  $\text{X}^2$  is not oxazole; and  $\text{X}^2$  is not thienyl when  $\text{Y}^2$  is~~



57. (Currently Amended) A compound according to claim 56, wherein  $X^2$  is a group represented by the formula:




wherein E is  $-(CH_2)_{1-3}-$ ,  $-O-CH_2-$ , or  $-S-CH_2-$ ; and


$R^6$  and  $R^7$  are each independently a hydrogen atom, an optionally substituted lower alkyl, carboxy, a lower alkyloxycarbonyl, an optionally substituted aminocarbonyl, an optionally substituted thienyl, or an optionally substituted phenyl; and

$R^8$  is a hydrogen atom or lower alkyl;

with the proviso that both  $R^6$  and  $R^7$  are not hydrogen atoms if  $X^2$  is



58. (Previously Presented) A compound according to claim 56, wherein  $X^2$  is a group represented by the formula:



$R^9$  is a hydrogen atom, an optionally substituted lower alkyl, a carboxy, a lower alkyloxycarbonyl, or an optionally substituted aminocarbonyl;

$R^{10}$  and  $R^{11}$  are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino.


59. (Currently Amended) A compound according to any one of claims 56 to 58, wherein  $Y^2$  is  $-NHCO-$ , or  $-CONH-$ ,  $-NHCH_2-$ , or  $-NHSO_2-$ .

60. (Previously Presented) A compound according to any one of claims 56 to 58, wherein  $Z^2$  is 1,4-phenylene.

61[[2]]. (Currently Amended) A compound of any one of claims 56 to 58, wherein  $A^2$  is a ring represented by the formula:

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



wherein  $R^8$  is a hydrogen atom or lower alkyl; M is ~~-S-, O-, CH<sub>2</sub>-, or N(R<sup>6</sup>-)~~, wherein ~~R<sup>6</sup> is a hydrogen atom or lower alkyl;~~  
and T is an oxygen atom or a sulfur atom.

62. (Previously Presented) A compound according to any one of claims 56 to 58, wherein the broken line represents the presence of a bond.

63. (Currently Amended) A compound represented by the formula III-A:




or its prodrug; or a pharmaceutically acceptable salt or solvate thereof, wherein  $R^9$  is a hydrogen atom, an optionally substituted lower alkyl, a carboxy, a lower alkyloxycarbonyl, or an optionally substituted aminocarbonyl;

$R^{10}$  and  $R^{11}$  are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino;


$Y^3$  is -NHCO- or -CONH-; and

$A^3$  is a ring represented by the formula:



wherein  $R^8$  is a hydrogen atom or lower alkyl; M is  $-S-$ ,  $-O-$ ,  $-CH_2-$ , or  $N(R^6)-$ , wherein  $R^6$  is a hydrogen atom or lower alkyl; and T is an oxygen atom or a sulfur atom.

64. (Currently Amended) A compound represented by the formula III-B:




or its prodrug; or a pharmaceutically acceptable salt or solvate thereof, wherein

$R^9$  is a hydrogen atom, an optionally substituted lower alkyl, a carboxy, a lower alkyloxycarbonyl, or an optionally substituted aminocarbonyl;

$R^{10}$  and  $R^{11}$  are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino;

$Y^3$  is  $-NHCO-$  or  $-CONH-$ ; and

$A^3$  is a ring represented by the formula:



wherein R<sup>8</sup> is a hydrogen atom or lower alkyl; M is ~~-S-, -O-, -CH<sub>2</sub>-, or -N(R<sup>6</sup>)-~~, wherein ~~R<sup>6</sup> is a hydrogen atom or lower alkyl;~~ and T is an oxygen atom or a sulfur atom.

65. (Previously Presented) A pharmaceutical composition containing at least one compound according to any one of claims 56 to 58, 63, or 64 as an active ingredient.

66. (Previously Presented) A pharmaceutical composition for exhibiting thrombopoietin agonism comprising as an active ingredient at least one compound according to any one of claims 56 to 58, 63, or 64.

67. (Previously Presented) A pharmaceutical composition comprising at least one compound according to any one of claims 56 to 58, 63, or 64, wherein the compound is a platelet production modifier.

Claims 68-69 cancelled.

70. (Currently Amended) A thrombopoietin receptor agonist composition comprising as an active ingredient a compound of the formula (I):



or its prodrug; or a pharmaceutically acceptable salt or solvate thereof, wherein

X<sup>1</sup> is an optionally substituted thiazole ringaryl, ~~optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or optionally substituted non-aromatic heterocyclic group;~~

Y<sup>1</sup> is ~~-NR<sup>A</sup>CO-(CH<sub>2</sub>)<sub>0-2</sub>-, NR<sup>A</sup>CO-(CH<sub>2</sub>)<sub>0-2</sub>-W-, NR<sup>A</sup>CO-CH=CH-,  
-W-(CH<sub>2</sub>)<sub>1-5</sub>-NR<sup>A</sup>CO-(CH<sub>2</sub>)<sub>0-2</sub>-, W-(CH<sub>2</sub>)<sub>1-5</sub>-CONR<sup>A</sup>-(CH<sub>2</sub>)<sub>0-2</sub>-, CONR<sup>A</sup>-(CH<sub>2</sub>)<sub>0-2</sub>-,  
-(CH<sub>2</sub>)<sub>0-5</sub>-NR<sup>A</sup>-SO<sub>2</sub>-(CH<sub>2</sub>)<sub>0-5</sub>-, (CH<sub>2</sub>)<sub>0-5</sub>-SO<sub>2</sub>-NR<sup>A</sup>-(CH<sub>2</sub>)<sub>0-5</sub>-, NR<sup>A</sup>-(CH<sub>2</sub>)<sub>0-2</sub>-,  
-NR<sup>A</sup>-CO-NR<sup>A</sup>-, NR<sup>A</sup>-CS-NR<sup>A</sup>-, N=C(SR<sup>A</sup>)-NR<sup>A</sup>-, NR<sup>A</sup>CSNR<sup>A</sup>CO-,  
-N=C(SR<sup>A</sup>)-NR<sup>A</sup>CO-, NR<sup>A</sup>-(CH<sub>2</sub>)<sub>1-2</sub>-NR<sup>A</sup>CO-, NR<sup>A</sup>CONR<sup>A</sup>NR<sup>F</sup>CO-, or  
-N=C(NR<sup>A</sup>R<sup>A</sup>)-NR<sup>A</sup>CO-,~~


wherein R<sup>A</sup> is each independently a hydrogen atom, an optionally substituted lower alkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteroaryl, or an optionally substituted heteroarylalkyl;

~~R<sup>F</sup> is a hydrogen atom or optionally substituted aryl;~~


~~W is an oxygen atom or a sulfur atom;~~

Z<sup>1</sup> is an optionally substituted phenylenearylene, ~~optionally substituted heteroarylene, optionally substituted non-aromatic heterocycle-diyl, or optionally substituted cycloalkyl-diyl;~~

A<sup>1</sup> is a thiazolidine ring represented by the formula:



or



FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com




wherein  $R^1$  and  $R^2$  are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom;  $R^3$  and  $R^4$  are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom;  $R^5$  is a hydrogen atom or lower alkyl; Q and V are each independently ~~O~~, chosen from -S-, CH<sub>2</sub>-, or and -NR<sup>B</sup>-, wherein  $R^B$  is a hydrogen atom or lower alkyl;

m is 1, ~~2~~, or 3; and

a broken line (---) represents the presence or absence of a bond.

71. (Currently Amended) A thrombopoietin receptor agonist composition according to claim 70, wherein  $X^1$  is an optionally substituted 5-member ~~heteroaryl~~ thiazole ring or a thiazole group represented by the formula:




wherein E is  $-(CH_2)_{1-3}-$ ,  $-O-CH_2-$ , or  $-S-CH_2-$ ;  $R^6$  and  $R^7$  are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl.

72. (Currently Amended) A thrombopoietin receptor agonist composition according to claim 70, wherein  $X^1$  is a group represented by the formula:

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



wherein E is  $-(CH_2)_{1-3}-$ ,  $-O-CH_2-$ , or  $-S-CH_2-$ ; and  $R^6$  and  $R^7$  are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl;  $R^8$  is a hydrogen atom or lower alkyl.


73. (Currently Amended) A thrombopoietin receptor agonist composition according to any one of claims 70 to 72, wherein  $Y^1$  is  $-NHCO-$ ,  $-CONH-$ ,  $-NHCH_2-$ , or  $-NHSO_2-$ .

74. (Previously Presented) A thrombopoietin receptor agonist composition according to any one of claims 70 to 72, wherein  $Z^1$  is 1,4-phenylene.

75. (Currently Amended) A thrombopoietin receptor agonist composition according to of any one of claims 70 to 72, wherein  $A^1$  is a ring represented by the formula:

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



wherein  $R^8$  is a hydrogen atom or lower alkyl; M is ~~-S-, O-, CH<sub>2</sub>-, or N(R<sup>6</sup>)-~~,

wherein ~~R<sup>6</sup> is a hydrogen atom or lower alkyl;~~

and T is an oxygen atom or a sulfur atom.

76. (Previously Presented) A thrombopoietin receptor agonist composition according to any one of claims 70 to 72, wherein the broken line represents the presence of a bond.